ABBV-295
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.
AbbVie · Phase 1 · Active, not recruiting · Enrollment 24
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| ABBV-295 Part 1 | n/r | n/r | n/r | n/r | n/r |
| Placebo for ABBV-295 Part 1 | n/r | n/r | n/r | n/r | n/r |
| ABBV-295 Part 2 | n/r | n/r | n/r | n/r | n/r |
| Placebo for ABBV-295 Part 2 | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.